Physician profile
Ish Singla
NPI 1215111422
$1,823.35
in general payments reported to CMS, 2019-2025
21 companies · $649 in 2025
The $649 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.71 · 2020: $25.67 · 2021: $152 · 2022: $658 · 2024: $271 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Travel and Lodging: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.39 |
| Travel and Lodging | $252.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $420.81 | 2021-2024 | Patientcare Link |
| Philips North America LLC | $341.75 | 2025 | Igt Devices Undivided, IV Other, Ambulatory Monitoring & Diagnostics Undivided |
| Actelion Pharmaceuticals US, INC. | $186.91 | 2022-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $176.12 | 2022 | |
| Amgen INC. | $133.42 | 2019-2024 | Repatha |
| Cleerly, INC. | $77.41 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.65 | 2022-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $63.72 | 2022 | |
| Pfizer INC. | $58.21 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $55.06 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $46.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $38.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.04 | 2025 | |
| Edwards Lifesciences Corporation | $22.92 | 2021 | |
| Inspire Medical Systems, INC. | $22.78 | 2025 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.20 | 2021 | |
| United Therapeutics Corporation | $17.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2025 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.17 | 2022 | |
| Lundbeck LLC | $11.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ish Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.